Analysis of dynamics of the drug list in the аffordable medicines program for treatment of cardiovascular diseases

• Main Authors: V. S. Huz, O. M. Zaliska
• Format: Article
• Language: Ukrainian
• Published: The State Expert Center of the Ministry of Health of Ukraine 2019-03-01
• Series: Фармацевтичний журнал
• Subjects: reimbursement; cardiovascular diseases; trade names of drugs; аffordable medicines program
• Online Access: https://pharmj.org.ua/index.php/journal/article/view/601/566

The implementation of the government program on reimbursement in Ukraine meets the requirements of WHO to ensure access to drugs, especially in the treatment of cardiovascular diseases (CVD). The list of TN drugs included in the «Affordable medicines» program increased by 22.6% in 2017–2018, and the proportion of compensated TNs has increased completely from 16.2% to 29.1%, that is, every third drug is released free of charge, which provides increased availability for patients with CVD. The purpose of the study was to analyze and compare the list that are available in the State Register of Ukraine for the treatment of CVD, and the range of INNs under the trade name (TN) and producers, which are part of the government program «Affordablee medicines» in dynamics for 2017–2018 years.We conducted an expert evaluation of the demand for drugs and the prospects for expanding the list of drugs in the reimbursement program by questioning pharmacists working in pharmacies involved in a government project in the Lviv and Ivano-Frankivsk regions. The objects of the study were the Orders of the Ministry of Health of Ukraine, the CMU Decisions, the Drug Registry for CVD, the cost for reimbursement in the program «Affordable Medicines». Questionnaires for assessing demand and prospects for expanding the list of reimbursement drugs were conducted. We used methods of comparative and content analysis, as well as logical and graphical analysis. We identified the groups of drugs presented in the «Available drugs» program, mainly foreign suppliers, therefore, the introduction of generic preparations of carvedilol, losartan, simvastatin and spironolactone is promising for domestic production, in order to increase consumption and reduce reimbursement costs, which will ensure availability for consumers. It is advisable to include domestic preparations of isosorbide dinitrate, hydrochlorothiazide, enalapril and atenolol in a program that will expand the list of these drugs in the «Affordable medicines» program. According to the expert opinion of pharmacists from Lviv and Ivano-Frankivsk regions, it is expedient to include from the group of lisinopril in the list of available drugs such as Lisinopril-Teva and Enap, and from the combined preparations of Enap H, Vasar H and Co-Preneca, which are often prescribed by doctors and they are in demand by patients.